free to fix/revise the prices, However in case of unreasonable increase in the price of decontrolled formulation, Government intervenes and prevails upon the company to bring it to a reasonable level.

(e) While fixing the price of controlled formulations notified or purchase price of the bulk drug, whichever is less, is taken into consideration.

(h) to (d) and (f) Various inputs such as bulk drugs, excipients, packing materials etc. run into a large number. Besides the number of formulation packs sold in the market at present are in thousands. Time and labour involved in the collection, collation and compilation of the information will not be commensurate with the results likely to be achieved.

Closing down of fertilizer units

1160. SHRI SUKOMAL SEN :

SHRI BHADRESWAR BURAGOHAIN :

SHRI JAGADISH JANI :

Will the PRIME MINISTER be pleased to state :

(a) whether there is any proposal under Government's consideration to close down some of the fertilizer units in the country ;

(b) if so, the details thereof;

(c) whether the matter has been referred to the BIFR ; and

(d) whether Government would reconsider the decision to wind up these units ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) to (c) The viability of chronically sick public sector fertilizer units is being examined. particularly in the context of budgetary constraints to meet the ever growing losses of such units. However, no decision has taken to wind up any public sector fertilizer unit. No reference has been to BIFR.

(d) Does not arise.

Personal hearing of Drug Companies

1161. SHRI RAJNI RANJAN SAHU :

SHRI H. HANUMANTHAPPA :

CHOUDHARY RAM SEWAK :

Will the PRIME MINISTER be pleased to state :

(a) whether Government have given personal hearing to any of the drug companies in cases of recovery under DPEA during 1991-92 ;

(b) if so, names of those companies and the dates when each was given the hearing ;

(c) what is the outcome of each hearing and what is the amount which stands final after hearing ;

(d) whether Government have issued any notice for recovery as an arrear of land revenue after the personal hearing ; and

(e) if so, names of the companies and when the notice was issued to each ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) and (b) The details of ersonal hearing granted to the

companies in the case of recovery under DPEA during 1991-92 are given in the statement (*see below*).

(c) to (e) Speaking orders after hearing were issued to the companies listed at Annexure I, except to M/s. Burroughs Welcome and M/s. Nicholas for the amount shown in column (4) of the annexure. Thereafter further representations have been received by this Ministry which are under examination. In the case of M/s. Burroughs Wellcome and M/s. Nicholas some more details/ data are yet to be received from them.

Statement

S. No.	Name of the Company	Date of hearing	Amount due (Rs. lakhs)	Date of notice for recovery of amount
1	2	3	4	5
1	M/s. Sandoz (Multivitamin) . . .	26-4-1991	74·68	24-6-91
2	M/s. Pfizer (Oxytetracycline) . . .	15-5-1991	87·61	12-12-91
3	M/s. Pfizer (Multivitamin)	17-7-1991	98·00	12-12-91
4	M/s. Burroughs Wellcome (Sulphamethoxazole)	5-8-1991	441·27	Yet to be finalised issued
5	M/s. Nicholas (Gentamycin) . . .	5-8-1991	53·03	Do.
6	M/s. S.G. Pharma (Oxyphenbutazone) .	8-8-1991	205·36	24-2-92
7	M/s. Abbott (Multivitamin) . . .	16-8-1991	182·38	12-12-91

M/s. Carews a shadow company of Mallaya Group

1162. SHRI H. HANUMANTHAPPA : Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 3084 given in Rajya Sabha on 19th December, 1991 and state :

(a) whether Government are aware that M/s. Carews is a shadow company of Mallaya Group aimed at siphoning off funds on the purchase of Ibuprofen and paracetamol ;

(b) whether it is a fact that the company had admitted that they are producing 7 formulations out of which four were price controlled at the time of crossing the limit of Rs. 50 lacs applicable to small scale sector ;

(c) if so names of those formulations and when each application was submitted ;

(d) when and what was the price approved and what was the price at which each was being sold ; and

(e) when did the company implement the approved price in each of these four cases ?